Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain

Biotechnology Progress

Volumn 23, Issue 4, 2007, Pages 964-971

  Raju, T Shantha ^a   Scallon, Bernard ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CYTOLOGY; GLYCOSYLATION; IMMUNOLOGY; MASS SPECTROMETERS; PHYSIOLOGICAL MODELS; SUGARS;

IMMUNOGLOBULINS; MATRIX-ASSISTED LASER DESORPTION-TIME-OF-FLIGHT-MASS SPECTROSCOPY; N-ACETYLGLUCOSAMINE;

PROTEINS;

CARBOHYDRATE; IMMUNOGLOBULIN G; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; PAPAIN; POLYSACCHARIDE;

ANIMAL; ARTICLE; CHEMICAL MODEL; CHEMISTRY; CHROMATOGRAPHY; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; METHODOLOGY; MOUSE; PROTEIN ENGINEERING;

ACETYLGLUCOSAMINE; ANIMALS; CARBOHYDRATES; CHROMATOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; MICE; MODELS, CHEMICAL; OLIGOSACCHARIDES; PAPAIN; POLYSACCHARIDES; PROTEIN ENGINEERING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 34547909649     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070118k     Document Type: Article

References (44)

1. Varki, A. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 1993, 3, 97-130.
2. Kobata, A. Structures and functions of the sugar chains of glycoproteins. Eur. J. Biochem. 1992, 209, 483-501.
3. Thotakura, N. R.; Blithe, D. L. Glycoprotein hormones: Glycobiology of gonadotrophins, thyrotrophin and free alpha subunit. Glycobiology 1995, 5, 3-10.
4. Kukuruzinska, M. A.; Lennon, K. Protein N-glycosylation: Molecular genetics and functional significance. Crit. Rev. Oral Biol. Med. 1998, 9, 415-448.
5. Spiro, R. G. Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 2002, 12, 43R-56R.
6. Kornfeld, R.; Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 1985, 54, 631-664.
7. Ashwell, G. Carbohydrate metabolism. Annu. Rev. Biochem. 1964, 33, 101-138.
8. Ashwell, G.; Morell, A. G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. Enzymol. Relat. Areas Mol. Biol. 1974, 41, 99-128.
9. Ashwell, G.; Harford, J. Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem. 1982, 51, 531-554.
10. Steer, C. J.; Ashwell, G. Hepatic membrane receptors for glycoproteins. Prog. Liver Dis. 1986, 8, 99-123.
11. Raju, T. S.; Briggs, J. B.; Chamow, S. M.; Winkler, M. E.; Jones, A. J. Glycoengineering of therapeutic glycoproteins: In vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry 2001, 40, 8868-8876.
12. Smedsrod, B.; Einarsson, M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb. Haemostasis 1990, 63, 60-66.
13. Jansen, R. W.; Molema, G.; Ching, T. L.; Oosting, R.; Harms, G.; Moolenaar, F.; Hardonk, M. J.; Meijer, D. K. Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge, or the combination of these features? J. Biol. Chem. 1991, 266, 3343-3348.
14. Noorrnan, F.; Barrett-Bergshoeff, M. M.; Rijken, D. C. Role of carbohydrate and protein in the binding of tissue-type plasminogen activator to the human mannose receptor. Eur. J. Biochem. 1998, 251, 107-113.
15. Ji, X.; Gewurz, H.; Spear, G. T. Mannose binding lectin (MBL) and HIV. Mol. Immunol. 2005, 42, 145-152.
16. Huber, S. C.; Hardin, S. C. Numerous posttranslational modifications provide opportunities for the intricate regulation of metabolic enzymes at multiple levels. Curr. Opin. Plant Biol. 2004, 7, 318-322.
17. Galili, U. Immune response, accommodation, and tolerance to transplantation carbohydrate antigens. Transplantation 2004, 78, 1093-1098.
18. Wildt, S.; Gerngross, T. U. The humanization of N-glycosylation pathways in yeast. Nat. Rev. Microbiol. 2005, 3, 119-128.
19. Gerngross, T. U. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat. Biotechnol. 2004, 22, 1409-1414.
20. Kobata, A. Function and pathology of the sugar chains of human immunoglobulin G, Glycobiology. Glycobiology 1990, 1, 5-8.
21. Arnold, J. N.; Wormald, M. R.; Sim, R. B.; Rudd, P. M.; Dwek, R. A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25, 21-50.
22. Raju, T. S.; Briggs, J. B.; Borge, S. M.; Jones, A. J. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000, 10, 477-486.
23. Axford, J. S. Glycosylation and rheumatic disease. Biochim. Biophys. Acta 1999, 1455, 219-229.
24. Yamada, E.; Tsukamoto, Y.; Sasaki, R.; Yagyu, K.; Takahashi, N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconjugate J. 1997, 14, 401-405.
25. Patel, T. P.; Parekh, R. B.; Moellering, B. J.; Prior, C. P. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem. J. 1992, 285, 839-845.
26. Jefferis, R.; Lund, J. Glycosylation of antibody molecules: Structural and functional significance. Chem. Immunol. 1997, 65, 111-128.
27. Hodoniczky, J.; Zheng, Y. Z.; James, D. C. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 2005, 21, 1644-1652.
28. Umana, P.; Gerdes, C. A.; Stone, D.; Davis, J. R.; Ward, D.; Castro, M. G.; Lowenstein, P. R. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 2001, 19, 582-585.
29. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M.; Hanai, N.; Shitara, K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278, 3466-3473.
30. Kaneko, Y.; Nimmerjahn, F.; Ravetch, J. V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313, 670-673.
31. Scallon, B. J.; Tam, S. H.; McCarthy, S. G.; Cai, A. N.; Raju, T. S. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 2007, 44, 1524-1534.
32. Raju, T. S.; Scallon, B. J. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem. Biophys. Res. Commun. 2006, 341, 797-803.
33. Anumula, K. R. Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. Anal. Biochem. 2006, 350, 1-23.
34. Bennett, K. L.; Smith, S. V.; Truscott, R. J.; Sheil, M. M. Monitoring papain digestion of a monoclonal antibody by electrospray ionization mass spectrometry. Anal. Biochem. 1997, 245, 17-27.
35. Malhotra, R.; Wormald, M. R.; Rudd, P. M.; Fischer, P. B.; Dwek, R. A.; Sim, R. B. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1995, 1, 237-243.
36. Kobata, A.; Mizuochi, T.; Endo, T.; Furukawa, K. Function and pathology of the sugar chains of human immunoglobulin G. Ciba Found. Symp. 1989, 145, 224-235.
37. Keusch, J.; Lydyard, P. M.; Isenberg, D. A.; Delves, P. J. β1,4-Galactosyltransferase activity in B cells detected using a simple ELISA-based assay. Glycobiology 1995, 5, 365-370.
38. Alavi, A.; Axford, J. Evaluation of beta 1,4-galactosyltransferase in rheumatoid arthritis and its role in the glycosylation network associated with this disease. Glycoconjugate J. 1995, 12, 206-210.
39. Zhu, J.; Yu, D. T. Matrix metalloproteinase expression in the spondyloarthropathies. Curr. Opin. Rheumatol. 2006, 18, 364-368.
40. Kageyama, Y.; Miyamoto, S.; Ozeki, T; Hiyohsi, M; Suzuki, M; Nagano, A. Levels of rheumatoid factor isotypes, metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in synovial fluid from various arthritides. Clin. Rheumatol. 2000, 19, 14-20.
41. Kotajima, L.; Aotsuka, S.; Fujimani, M.; Okawa-Takatsuji, M.; Kinoshita, M.; Sumiya, M.; Obata, K. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin. Exp. Rheumatol. 1998, 16, 409-415.
42. Di Girolamo, N.; Tedla, N.; Lloyd, A.; Wakefield, D. Expression of matrix metalloproteinases by human plasma cells and B lymphocytes. Eur. J. Immunol. 1998, 28, 1773-1784.
43. Sedlacek, R.; Mauch, S.; Kolb, B.; Schatzlein, C.; Eibel, H.; Peter, H. H.; Schmitt, J.; Krawinkel, U. Matrix metalloproteinase MMP-19 (RASI-1) is expressed on the surface of activated peripheral blood mononuclear cells and is detected as an autoantigen in rheumatoid arthritis. Immunobiology 1998, 198, 408-423.
44. Fiedorczyk, M.; Klimiuk, P. A.; Sierakowski, S.; Gindzienska-Sieskiewicz, E.; Chwiecko, J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. J. Rheumatol. 2006, 33, 1523-1529.